Investigational drug · Phase 3
Bezuclastinib
Also called: CGT9486, PLX9486
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Systemic Mastocytosis (AdvSM), SM With an Associated Hematologic Neoplasm (SM-AHN), Mast Cell Leukemia (MCL).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
7
Any phase or sponsor naming "Bezuclastinib"
First trial start
2021
Nov 9, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bezuclastinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Systemic Mastocytosis (AdvSM)
- SM With an Associated Hematologic Neoplasm (SM-AHN)
- Mast Cell Leukemia (MCL)
- Aggressive Systemic Mastocytosis (ASM)
- SSM
- Mastocytosis, Indolent
- Mastocytosis, Systemic
- Mastocytosis
- ISM
- BMM
Approved drugs for the same conditions: Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Bezuclastinib" as an intervention, largest first.
- (Peak) A Phase 3 Randomized Trial of Bezuclastinib (CGT9486)+Sunitinib vs. Sunitinib in Participants With Gastrointestinal Stromal TumorsPivotal-lookingRecruiting
Cogent Biosciences, Inc.Industry
NCT05208047 · 482 participants (planned) · Start Apr 14, 2022 · Primary completion Sep 30, 2025
Drug: Bezuclastinib; Bezuclastinib and 7 more · For: Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 126 sites in all
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruiting
IDRX, Inc., a wholly owned subsidiary of GSK, LLCIndustry
NCT05489237 · 276 participants · Start Aug 3, 2022 · Primary completion Mar 10, 2027
Drug: IDRX-42 · For: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease and 2 more
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 31 sites in all
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisPivotal-lookingActive, not recruiting
Cogent Biosciences, Inc.Industry
NCT05186753 · 237 participants (planned) · Start Jun 27, 2022 · Primary completion May 22, 2025
Drug: Bezuclastinib Tablets (Formulation A); Bezuclastinib Tablets (Formulation B) and 1 more · For: SSM; Mastocytosis, Indolent; Mastocytosis, Systemic and 5 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
Cogent Biosciences, Inc.Industry
NCT04996875 · 140 participants (planned) · Start Nov 9, 2021 · Primary completion Sep 19, 2025
Drug: bezuclastinib · For: Advanced Systemic Mastocytosis (AdvSM); SM With an Associated Hematologic Neoplasm (SM-AHN); Mast Cell Leukemia (MCL) and 1 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Duarte, California · 42 sites in all
- SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GISTActive, not recruiting
Sarcoma Alliance for Research through CollaborationAcademic, hospital or other
NCT06208748 · 40 participants (planned) · Start Aug 1, 2024 · Primary completion Jun 2026
Drug: Bezuclastinib in combination with sunitinib · For: Gastrointestinal Stromal Tumors; GIST
Sites: Miami, Florida; Boston, Massachusetts; Portland, Oregon · 4 sites in all
Cogent Biosciences, Inc.Industry
NCT06948955
Drug: Bezuclastinib; Sunitinib · For: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
Sites: Phoenix, Arizona; Los Angeles, California; Aurora, Colorado · 26 sites in all
Cogent Biosciences, Inc.Industry
NCT06915766
Drug: Bezuclastinib · For: Systemic Mastocytoses, Indolent; Systemic Mastocytoses, Aggressive
Sites: La Jolla, California; Los Angeles, California; Normal, Illinois · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Targeted KIT inhibitors: paradigm shift in the treatment of systemic mastocytosis.
Abbas HA, Chifotides HT, Bose P · Expert Opin Investig Drugs 2026
- Gastrointestinal stromal tumors: can we do better than sunitinib in the second line?
Rutkowski P, Klimczak A · Expert Opin Pharmacother 2026
- Emerging drugs for the treatment of gastrointestinal stromal tumors: a spotlight on bezuclastinib and the evolving treatment landscape.
Pozas J, Napolitano A, Jones RL · Expert Opin Emerg Drugs 2026
- Evaluating bezuclastinib for the treatment of advanced gastrointestinal stromal tumours.
Italiano A · Expert Opin Pharmacother 2026
- Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.
Jingnuo D, Huachuan Z, Da Z, et al. · J Gastroenterol Hepatol 2026
- Tyrosine Kinase Inhibitors for the Treatment of Mast Cell Diseases: Review and Update.
Carpio-Escalona LV, Prieto-García A, Morales-Cabeza C, et al. · J Investig Allergol Clin Immunol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.